

1 **Genetic Evidence for Soluble VEGFR2 as a Protective Factor Against Macular Pucker**

2

3 Qi Gao<sup>1\*</sup> and Jinglong Guo<sup>1\*</sup>

4

5 1 Department of Cardiovascular Diseases, the First Hospital of Jilin University, Changchun

6 130021, China

7

8 \* Correspondence:

9 Jinglong Guo: [guojl14@mails.jlu.edu.cn](mailto:guojl14@mails.jlu.edu.cn)

10 Qi Gao: [gaoqi2019@jlu.edu.cn](mailto:gaoqi2019@jlu.edu.cn)

11

12

13

14

15

16

17

18

19

20

21

22

23

24 **Abstract**

25 **Background:** Identifying factors that protect against macular pucker (MP) is crucial for  
26 developing effective treatments. We hypothesize that soluble vascular endothelial growth factor  
27 receptor 2 (sVEGFR2), a decoy receptor for VEGF signaling, may provide such protection.

28  
29 **Methods:** We performed a genome-wide association (GWAS) meta-analysis on three  
30 independent studies of sVEGFR2 protein quantitative trait loci (pQTL), which was used to  
31 identify novel variants and select variants strongly associated with sVEGFR2 levels. We  
32 investigated the association between sVEGFR2 levels and the risk of MP using *cis*-Mendelian  
33 Randomization (*cis*-MR) and Bayesian colocalization. We also used the UKB-PPP study of  
34 sVEGFR2 pQTL, which used a different method for measuring plasma protein, to validate the  
35 results from *cis*-MR and colocalization.

36  
37 **Results:** GWAS meta-analysis identified four novel variants associated with sVEGFR2 levels,  
38 rs9411335 (*MED27*), rs6992534 (*ERII*), rs11893824 (*LIMS2*), and rs7678559 (*PCDH7*). *Cis*-  
39 MR analysis suggested that higher levels of sVEGFR2, genetically predicted using the meta-  
40 analysis dataset, were associated with a lower risk of MP (OR 0.86, 95% CI 0.77-0.95,  $P = 4.6 \times$   
41  $10^{-3}$ ). Colocalization supported shared genetic variants in the *VEGFR2* gene region between  
42 sVEGFR2 and MP (PPH4 = 0.92). Using sVEGFR2 pQTL from UKB-PPP study, sVEGFR2's  
43 inverse association with MP was validated by *cis*-MR (OR 0.86, 95% CI 0.78-0.96,  $P = 4.4 \times 10^{-3}$ )  
44 and colocalization (PPH4 = 0.95). Sensitivity analyses showed no evidence of pleiotropy or  
45 reverse causality, though some heterogeneity was found.

46

47 **Conclusions:** Our study suggested that sVEGFR2 has a protective effect against MP and could  
48 be a potential therapeutic target. Further research is necessary to elucidate its protective  
49 mechanisms and validate its translational implications.

50

51 **Keywords:** soluble VEGFR2, macular pucker, causally protective effects, GWAS meta-analysis,  
52 *cis*-Mendelian Randomization, Bayesian colocalization

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

## 70 **Background**

71 Macular pucker (MP), also known as epiretinal membrane, is a potentially sight-threatening  
72 vitreoretinal disease. It is characterized by a sheet of abnormal, thin, fibrotic tissue that grows on  
73 the surface of the macula that is responsible for detailed central vision. The prevalence of MP  
74 ranges from 7% to 11.8%, with aging being the primary nonmodifiable risk factor. Surgical  
75 intervention, such as vitrectomy with membrane peeling, is the current standard of care for  
76 symptomatic MP cases (1-3). However, pharmacological approaches targeting MP pathogenesis  
77 are still largely lacking, likely due to an insufficient understanding of the causal factors involved  
78 (1-3).

79

80 The MP pathogenesis involves a complex interplay among various cells and acellular factors,  
81 including angiogenesis, inflammation, and fibrosis at the vitreoretinal interface (4-6). VEGFR2  
82 is expressed in retinal pigment epithelium and endothelial cells within MP tissues, indicating its  
83 potential role in the disease's pathogenesis (7-9). VEGFR2 signaling, which is activated through  
84 the binding of VEGF-A, promotes crucial processes in endothelial cells of blood vessels such as  
85 proliferation, migration, and survival (10). In addition, VEGFR2 signaling is also implicated in  
86 fibrosis and inflammation (11). Of note, soluble forms of VEGFR2 (sVEGFR2) can regulate  
87 VEGFR2 signaling by acting as decoy receptors for VEGF-A (12-14). In mice, sVEGFR2 has  
88 been shown to suppress corneal neovascularization and lymphangiogenesis (15). In humans,  
89 sVEGFR2 has been suggested to play an important role in macular edema through regulating  
90 angiogenesis (16, 17). Despite this, the causal relationships between sVEGFR2 and human  
91 retinal diseases such as MP remain not inferred.

92

93 Mendelian randomization (MR) is a method used to evaluate the potential causality of a  
94 modifiable exposure on an outcome by utilizing genetic variants as instrumental variables (18).  
95 Because genetic variants are randomly assorted during gamete formation and fixed at  
96 conception, MR estimates could minimize bias resulting from confounding factors or reverse  
97 causality. *Cis*-MR specifically refers to MR studies that use genetic variants from gene-restricted  
98 regions of pharmacological protein of interest, and it is typically employed for drug target  
99 validation (19). Bayesian colocalization analysis evaluates whether two distinct traits are affected  
100 by the same causal variants, making it an important complementary analysis to appraise the  
101 validity and strength of a *cis*-MR estimate (20). Meta-analysis of independent genome-wide  
102 association studies (GWAS) combines data from multiple studies into a single, large-scale dataset  
103 (21). This approach not only helps in discovering new genetic variants but also enhances the  
104 reliability and robustness of results when used in MR and colocalization studies (22). Using  
105 these advanced genetic methodologies, we investigated the relationship between plasma levels of  
106 sVEGFR2 and MP risk.

107

## 108 **Methods**

### 109 **Data source**

110 Information of the data sources used in this study was summarized in Supplementary table 1. The  
111 study relied on summary-level GWAS data that have been available publicly, ethical approvals  
112 were obtained in all original studies. sVEGFR2 pQTL used for meta-analysis included Interval  
113 study, with 3,301 Europeans (23); AGES study, with 5,361 Icelanders (24); and DECODE study,  
114 with 35,559 Icelanders (25). The plasma protein in these studies were measured by SomaScan  
115 platform. In addition, sVEGFR2 pQTL from the UK Biobank Pharma Proteomics Project (UKB-

116 PPP) study (plasma protein measured by Olink and included 33,822 UK participants) was also  
117 used (26). In the original study, plasma proteins were measured with standard quality controls  
118 and adjusted for year of birth, sex, and year of sample collection. GWAS of MP (N=4,599 cases,  
119 N=413,784 controls) and other macula conditions were from the 11th release of FinnGen study,  
120 with cases being defined based on International Classification of Diseases (ICD-10). The original  
121 GWAS of eye diseases in the FinnGen study were adjusted for age, sex, and genetic principal  
122 components (27).

123

#### 124 **Genome-wide association studies of sVEGFR2 pQTL**

125 We performed a meta-analysis on plasma sVEGFR2 pQTL using data from three independent  
126 studies Interval, AGES, and DECODE. To account for potential heterogeneity in genetic  
127 associations, due to difference participants and/or environment, we performed the meta-analysis  
128 of random effects using METAL (version 2011-02-25) (28). This comprehensive analysis  
129 resulted in a dataset of 44,221 individuals and over 25 million variants. The base pair positions in  
130 original Interval and AGES studies were based on GRCh37, which were transformed to GRCh38  
131 using LiftOver (version 1.28.0 ) (29). Finally, all the datasets used in the studies were based  
132 GRCh38. Using PLINK 2.00 alpha (30), independent lead genetic variants were identified by  
133 filtering associations on a genome-wide significant P-value of  $5 \times 10^{-8}$  and clumping to a  $R^2$  of  
134 0.001 with 10000kb window based on the European 1000 Genome Project reference panel. The  
135 nearest protein-coding genes were identified using Open Targets, with CADD scored evaluated  
136 (31). Combined Annotation-Dependent Depletion (CADD) has been widely used to predict the  
137 deleteriousness of variants throughout the human genome (32). Novel variants were identified by  
138 excluding variants that located within 500kb of loci in original studies (Interval, AGES, and

139 DECODE) and variants of genome-wide significant in the sVEGFR2 pQTL of UKB-PPP study  
140 (Supplementary table 2).

141

## 142 **Selection of genetic instruments**

143 All above mentioned datasets of sVEGFR2 pQTL (namely Internal, AGES, DECODE, Meta-  
144 analysis, and UKB-PPP study) were used to select genetic instruments for sVEGFR2. Genetic  
145 variants associated with sVEGFR2 with genome-wide significance and located  $\pm 100$  kilobase  
146 (kb) of *VEGFR2* gene (chromosome 4, GRCh38 position 55078481-55125595) were selected.  
147 These variants were then pruned to remove SNPs in high linkage disequilibrium ( $R^2 < 0.1$ )  
148 within a 100kb window based on the 1000 Genomics European reference panel. To select  
149 variants associated with MP, a GWAS-correlated P-value  $< 5 \times 10^{-8}$  and linkage disequilibrium  
150 (LD)  $R^2 < 0.001$  within a 10,000kb window based on the European 1000 Genome Project  
151 reference panel. Variants with F-statistic  $< 10$  and minor allele frequency (MAF)  $< 0.01$  were  
152 excluded. F-statistic  $> 10$  indicates robust instrument strength, calculated by  $F = R^2(N - K -$   
153  $1)/K(1 - R^2)$ , where  $R^2$  is the proportion of variance in the exposure explained by genetic  
154 variants, K is the number of instruments, and N is the sample size.  $R^2$  estimates the proportion of  
155 variance in the phenotype explained by the genetic variant,  
156  $R^2 = 2 \times (\text{Beta}/\text{SD})^2 \times (\text{MAF}) \times (1 - \text{MAF})$ , where Beta represents the per-allele effect size of the  
157 association between each variant and the phenotype, and SD denotes the standard deviation (33).  
158 Detailed information on the genetic variants was provided in Supplementary table 3.

159

## 160 ***cis*-MR analysis**

161 We performed MR analyses following the STROBE-MR guidelines (34). MR study should be  
162 conducted based on three core principles: (1) relevance, the genetic instruments should be  
163 significantly associated with the exposure; (2) independence, the genetic instruments should not  
164 be associated with any potential confounder and (3) exclusion restriction, the genetic instruments  
165 should not directly affect the outcome except via the way of exposure (18). Genetic correlations  
166 between exposure and outcome for each variant were harmonized by aligning effects alleles,  
167 with exclusion of palindromic variants. Prior to each MR analysis, MR Pleiotropy RESidual Sum  
168 and Outlier (MR-PRESSO) was applied to identify and remove potential outliers (35). The  
169 causal effects were assessed mainly using inverse variance-weighted (IVW) method of MR (36).  
170 This method assumes that outcomes are influenced only by the exposure, setting the intercept at  
171 zero (36). We also performed MR Egger, which allows sensitivity tests to rule out potential bias  
172 induced by horizontal pleiotropy using the inclusion of the intercept in the regression analysis,  
173 and  $P < 0.05$  was considered significant for the presence of horizontal pleiotropy (37). MR-  
174 PRESSO global test was used to assess the presence of horizontal pleiotropy and  $P$  value  $< 0.05$   
175 was considered significant for the presence of horizontal pleiotropy (35). The Cochran's  $Q$  test  
176 was used to assess heterogeneity, and  $P < 0.05$  was considered significant for the presence of  
177 heterogeneity (38). The leave-one-out plots were used to assess the influence of individual  
178 variants on observed associations (38). The MR Steiger directionality tests were used to assess  
179 whether there was reverse causality in our *cis*-MR study (39). Reverse MR with IVW method  
180 aimed to evaluate whether MP was causally associated with sVEGFR2 levels and was employed.  
181 No proxy variants were used across the MR analyses.

182

183 **Bayesian colocalization analysis**



184 Bayesian colocalization was performed to investigate whether sVEGFR2 and MP shared genetic  
185 variants within  $\pm 100$  kb around the *VEGFR2* gene. The "coloc" package (version 5.2.3) in R  
186 (version 4.4.1) was utilized for these analyses (40), with visualization facilitated by the  
187 "locuscomparer" package (version 1.0.0) (41). The posterior probability of hypothesis 4  
188 (PPH4)  $> 0.8$  indicated strong evidence of colocalization.

189

## 190 **Statistical analysis**

191 The IVW method was used to assess the causal effect. MR results were reported as odds ratios  
192 (OR) with 95% confidence interval (CI) per one-SD increase in log-transformed unit of  
193 sVEGFR2 levels. All MR analyses were two-sided and performed using package  
194 'TwoSampleMR' (version 0.6.4) in R (version 4.4.1).  $P < 0.05$  was considered statistically  
195 significant.

196

## 197 **Results**

### 198 **Discovery of novel sVEGFR2-associated variants through genome-wide association meta-** 199 **analysis**

200 The overall study design was shown in Figure 1. Our meta-analysis on sVEGFR2 pQTL of  
201 Interval, AGES, and DECODE studies identified 30 independent variants with genome-wide  
202 significance. We mapped their corresponding genes and searched their CADD scores using Open  
203 Targets (31). Among these, six variants were considered novel, as they located outside the  $\pm 500$   
204 kb window of known loci identified in the original studies (Interval, AGES, and DECODE).  
205 After further excluding variants with genome-wide significance found in the UKB-PPP study,  
206 which included 33822 European individuals with over 20 million variants and used Olink

207 technology for plasma protein measurement (26), four novel variants remained. Specifically,  
 208 these were rs9411335 (*MED27*, Mediator Complex Subunit 27), rs6992534 (*ERII*,  
 209 Exoribonuclease 1), rs11893824 (*LIMS2*, LIM Zinc Finger Domain Containing 2), and  
 210 rs7678559 (*PCDH7*, Protocadherin 7) (Table 1 and Supplementary figure 1).

**Table 1 Variants reported for plasma levels of sVEGFR2 in the meta-analysis of Interval, AGES, and DECODE datasets**

SNP	CH R	POS (hg38)	Nearest gene	CAD D score	EA	NEA	EAF	BET A	SE	P	Directi on
<b>Novel variants</b>											
rs9411335	9	13202583 7	<i>MED27</i>	0.754	a	g	0.687 6	- 0.042 9	0.007 8	4.48E- 08	---
rs6992534	8	8949289	<i>ERII</i>	0.05	a	c	0.300 2	- 0.043 7	0.007 9	2.71E- 08	---
rs1189382 4	2	12768113 5	<i>LIMS2</i>	6.02	a	g	0.374 1	- 0.052 1	0.008 2	1.87E- 10	---
rs7678559	4	30829441	<i>PCDH7</i>	0.015	t	c	0.609 7	- 0.047 1	0.008	4.13E- 09	---
<b>Previously reported variants</b>											
rs6180416 4	1	16165323 5	<i>FCGR2B</i>	3.41	c	g	0.770 3	- 0.066 9	0.010 1	4.00E- 11	-?-
rs6183029 1	1	22082780 0	<i>MTARC1</i>	13.2	a	c	0.284 6	0.079 1	0.011 8	2.37E- 11	+++
rs1249383 0	3	98687950	<i>ST3GAL6</i>	2.23	t	c	0.457 3	0.164 3	0.007 2	7.33E- 114	+++
rs3423103 7	4	55106779	<i>KDR</i>	24.4	a	g	0.274 5	0.929 7	0.023 1	1.12E- 352	+++
rs2305948	4	55113391	<i>KDR</i>	23.3	t	c	0.705 9	0.354	0.014	6.46E- 142	+++
rs6229773 1	4	53788196	<i>LNX1</i>	3.41	t	c	0.745 9	- 0.127 8	0.021 3	2.06E- 09	--+
rs3529734 3	4	57096955	<i>IGFBP7</i>	7.38	t	c	0.262 3	- 0.085 6	0.013 9	6.88E- 10	---
rs6823788	4	55669371	<i>NMU</i>	1.77	a	t	0.550 8	0.064 8	0.007 4	2.76E- 18	+++
rs5784903 2	4	47246080	<i>COMMD 8</i>	N/A	ccc	cccc	0.003 2	0.403 8	0.072 5	2.59E- 08	+??
rs1126253 34	6	31505576	<i>MICB</i>	0.153	t	c	0.004 9	0.363 5	0.062 6	6.28E- 09	+??
rs1875701 81	6	32196810	<i>GPSM3</i>	8.84	t	c	0.768 3	0.106 6	0.015 4	4.45E- 12	++-
rs8192585	6	32221046	<i>NOTCH4</i>	0.046	a	g	0.757 6	0.163 5	0.017 4	5.69E- 21	+++
rs932589	6	13676200 0	<i>MAP3K5</i>	7.23	t	c	0.561 7	- 0.048 5	0.007 4	5.25E- 11	---
rs3578370 4	8	10495403 0	<i>ZFPM2</i>	16.6	a	g	0.704	0.060 5	0.010 5	9.44E- 09	+++
rs600038	9	13327635 4	<i>ABO</i>	7.6	t	c	0.843 8	0.440 6	0.007 8	3.18E- 688	+++
rs1467981 34	9	13290803 8	<i>AK8</i>	1.15	aattgtgccactg ca	aattgtgccactg cg	0.017 7	0.315 3	0.031 6	2.04E- 23	+??
rs3124774	9	13349638 1	<i>SLC2A6</i>	0.912	tgcatcacgcga	tgcatcacgcg	0.392 1	0.066 3	0.008 6	9.95E- 15	+??

rs117608058	9	133540282	<i>ADAMTS L2</i>	7.32	a	g	0.9763	-0.1911	0.0266	6.20E-13	-??
rs11603123	11	126435600	<i>ST3GAL4</i>	15.4	a	g	0.7668	0.2884	0.0187	2.03E-53	+++
rs117603193	11	126390969	<i>ST3GAL4</i>	5.53	a	g	0.2379	0.2121	0.0287	1.51E-13	+++
rs112564808	11	126177295	<i>RPUSD4</i>	1.81	t	c	0.2092	-0.1736	0.0266	6.66E-11	---
rs12808285	11	95449298	<i>SESN3</i>	0.497	t	g	0.7159	0.0886	0.0134	3.83E-11	+++
rs10649122	12	57256822	<i>STAC3</i>	5.58	ct	ctctct	0.2653	0.0518	0.0093	2.17E-08	+??
rs704	17	28367840	<i>SEBOX</i>	0.199	a	g	0.5045	-0.0522	0.0072	4.60E-13	---
rs61102135	17	83072806	<i>METRNL</i>	4.48	g	ga	0.1457	0.0893	0.0145	7.72E-10	+?+
rs143501783	17	7897001	<i>NAA38</i>	3.12	t	c	0.0866	-0.2142	0.0359	2.40E-09	-?-

SNP, single nucleotide polymorphism; CHR, chromosome; POS, position; CADD, combined annotation-dependent depletion; EA, effect allele; NEA, other allele; EAF, effect allele frequency

211

### 212 3.2 *Cis*-MR and colocalization suggested sVEGFR2 as a protective factor against MP

213 *Cis*-MR analysis using IVW method indicated that genetically predicted higher levels of  
 214 sVEGFR2 were associated with a reduced risk of MP (Figure 2). Specifically, for sVEGFR2  
 215 levels inferred from genetic variants in the meta-analysis, the odds ratio (OR) for MP was 0.86  
 216 (95% CI: 0.77-0.95,  $P = 4.6 \times 10^{-3}$ ), while for sVEGFR2 levels inferred from the UKB-PPP  
 217 study, the OR was 0.86 (95% CI: 0.78-0.96,  $P = 4.4 \times 10^{-3}$ ). Additionally, sVEGFR2 levels  
 218 predicted by genetic variants from the Interval and DECODE studies, but not the AGES study,  
 219 also showed an inverse association with MP (Figure 2 and Supplementary figure 2).

220

221 To validate these findings, we conducted Bayesian colocalization analyses (Figure 3). The results  
 222 revealed that the *VEGFR2* gene region was shared between sVEGFR2 pQTL and MP across all  
 223 analyses. The PPH4 was as follows: 0.93 for the Interval study, 0.93 for the AGES study, 0.92 for  
 224 the DECODE study, 0.92 for the meta-analysis, and 0.95 for the UKB-PPP study (Figure 3).

225

### 226 Tests for sensitivity and reverse causality

227 To ensure the robustness of our findings, we conducted a series of rigorous sensitivity analyses in  
228 our *cis*-MR study to examine the relationship between sVEGFR2 levels and MP risk. We  
229 employed MR-Egger intercept and MR-PRESSO global tests to assess horizontal pleiotropy.  
230 Both tests consistently showed no evidence of horizontal pleiotropy across all examined  
231 associations (Supplementary table 4). However, Cochran's Q tests revealed significant  
232 heterogeneity between sVEGFR2 levels in the meta-analysis and the UKB-PPP study, and the  
233 outcome in our *cis*-MR analyses (Supplementary table 4). Despite this, the heterogeneity was  
234 deemed acceptable given that our primary *cis*-MR results were estimated using the IVW method.  
235 Additionally, leave-one-out plots suggested that no single genetic variant disproportionately  
236 influenced the overall results of our *cis*-MR study (Supplementary figure 3).

237

238 To address the potential for reverse causality, we performed MR Steiger directionality tests,  
239 which provided no evidence of reverse causation in the significant *cis*-MR results  
240 (Supplementary table 5). Further, we conducted reverse MR analyses, treating MP as the  
241 exposure and sVEGFR2 levels as the outcome. These analyses revealed that only the DECODE  
242 study and the meta-analysis contained genetically valid variants that also intersected with MP  
243 (Supplementary table 6). Importantly, no association between MP and sVEGFR2 levels was  
244 found, reinforcing the absence of reverse causality in our initial *cis*-MR findings (Supplementary  
245 table 6).

246

## 247 **Discussion**

248 We presented a large-scale GWAS meta-analysis of SomaLogic values for plasma sVEGFR2,  
249 which enabled the discovery of four novel variants associated with sVEGFR2. This meta-

250 analysis, along with an independent dataset for sVEGFR2 pQTL (measured by Olink) in the  
251 UKB-PPP study, further enabled MR analysis sourcing *cis*-variants within and around the  
252 *VEGFR2* gene to explore potential associations between sVEGFR2 and MP. Furthermore, the  
253 *cis*-MR results were supported by Bayesian colocalization analyses, showing the presence of  
254 shared genetic variants between sVEGFR2 and MP. To the best of our knowledge, our study  
255 provided the first human causal evidence that higher sVEGFR2 levels were associated with a  
256 reduced risk of MP. Therefore, these analyses proposed sVEGFR2 as a promising target for  
257 preventing or treating MP.

258  
259 VEGFR2, a receptor primarily known for its role in endothelial cells, is also expressed in the  
260 retinal pigment epithelium (RPE) (7-9). RPE is a crucial monolayer located between the  
261 neuroretina and choroid and is implicated in the pathogenesis of MP (42). Dysregulation of  
262 VEGFR2 signaling in the RPE can lead to aberrant endoplasmic reticulum stress, oxidative  
263 stress, and inflammatory responses (43), all of which could be critical factors in MP  
264 development. Abnormal blood vessel formation is also observed in vascular MP, highlighting the  
265 significance of VEGFR2's functions beyond its canonical roles in endothelial cells. VEGFR2's  
266 traditional functions in endothelial cells include regulating blood vessel formation and  
267 permeability (10). These functions may also influence MP pathogenesis in the retina. The  
268 protective role of sVEGFR2 in MP is likely multifaceted. As a decoy receptor, sVEGFR2 binds  
269 VEGF-A, competing with membrane-bound VEGFR2 (mVEGFR2) (12). This interaction can  
270 modulate downstream processes such as angiogenesis, lymphangiogenesis, inflammation, and  
271 fibrotic responses in the macula (11), potentially preventing or alleviating MP progression. By  
272 sequestering VEGF-A, sVEGFR2 can also mitigate VEGF-A/mVEGFR2-mediated vascular

273 permeability, contributing to retinal vasculature stabilization and potentially reducing MP  
274 pathogenesis (10). Further research is essential to fully elucidate sVEGFR2's protective  
275 mechanisms in MP and to explore its potential therapeutic applications.

276

277 In addition, the meta-analysis identified four novel genetic variants associated with sVEGFR2:  
278 rs9411335 (MED27, Mediator Complex Subunit 27), rs6992534 (ERI1, Exoribonuclease 1),  
279 rs11893824 (LIMS2, LIM Zinc Finger Domain Containing 2), and rs7678559 (PCDH7,  
280 Protocadherin 7). Searches in the GWAS catalog did not reveal any studies linking these variants  
281 to sVEGFR2 or mVEGFR2. Moreover, the relationship between mVEGFR2, which is expressed  
282 on the cell surface, and the levels of sVEGFR2 secreted into circulation remains poorly  
283 understood. Further investigation of these variants could reveal important regulation mechanisms  
284 of VEGFR2 signaling and related diseases.

285

286 It has been observed that MP can be linked to various macular conditions (2). To explore whether  
287 sVEGFR2 might influence MP through its association with these conditions, we examined  
288 whether sVEGFR2 was related to several macular disorders. Interestingly, our analysis, using  
289 genetic variants identified from meta-analyses or the UKB-PPP study to predict sVEGFR2  
290 levels, found no significant association with a range of macular conditions, including macular  
291 hole, retinal detachments and breaks, diabetic retinopathy, retinal vascular disorders, and retinal  
292 vascular occlusions (Supplementary figure 4). These findings suggested that the association  
293 between sVEGFR2 and MP may be specific to MP itself, rather than being influenced by a  
294 broader relationship with these other macular conditions.

295

296 Our study had several major strengths. We utilized a GWAS meta-analysis to generate a large-  
297 scale sVEGFR2 pQTL and further validated these findings with an independent large-scale  
298 sVEGFR2 pQTL from the UKB-PPP study. These studies represent plasma protein  
299 measurements obtained via SomaScan and Olink, respectively. The integration of these two  
300 datasets not only maximized the inclusion of genetic variants associated with sVEGFR2 but also  
301 significantly improved the robustness and reliability of our findings by complementing each  
302 other. Additionally, genetic variants were selected from regions  $\pm 100$ kb of *VEGFR2* gene. These  
303 variants were likely to have a significant impact on protein expression compared to their impact  
304 on other traits. Therefore, *cis*-MR was less likely to violate the assumption of 'no horizontal  
305 pleiotropy'. Besides, utilizing *cis*-MR for protein risk factors could enhance the reliability of  
306 causal inferences by aligning with Crick's central dogma. This principle could support a  
307 sequential flow from gene to protein to disease, which could be more plausible than a gene to  
308 disease to protein pathway, particularly in studies using population-based samples. Therefore,  
309 *cis*-MR could effectively minimize the likelihood of reverse causality. Furthermore, Bayesian  
310 colocalization analysis is a powerful method used to determine whether two different traits or  
311 genomic signals are influenced by the same causal genetic variants. Integrating *cis*-MR with  
312 colocalization could synergistically harness their respective strengths, reinforcing the causal  
313 relationship between sVEGFR2 and MP.

314

315 To appreciably understand the results, several limitations in the study should be discussed. While  
316 we identified genetic variants significantly associated with sVEGFR2 levels, they explained only  
317 a small proportion of the total variance and should not be considered as exact proxies of the  
318 exposure. Moreover, MR effect estimates assume lifelong exposure to altered protein levels (e.g.,

319 sVEGFR2), which could potentially be diverging from observational associations and  
320 therapeutic interventions. Besides, sVEGFR2 levels measured in plasma from the published  
321 GWAS pQTL analysis may not accurately represent their concentrations or biological functions  
322 in retinal tissues, where they could potentially play a pivotal role in MP pathogenesis. This  
323 indicated the need for cautious interpretation of our findings. Our study primarily highlighted the  
324 causally protective effects of sVEGFR2 on MP, yet the underlying biological mechanisms  
325 require further investigation. Lastly, our study included only individuals of European descent,  
326 which could limit the generalizability to other populations.

327

## 328 **Conclusion**

329 In conclusion, our study employed GWAS meta-analysis of sVEGFR2 pQTL and utilized *cis*-  
330 MR and colocalization analyses to provide robust genetic evidence supporting a protective effect  
331 of sVEGFR2 against MP. These findings suggested sVEGFR2 as a promising drug target for MP  
332 and warranted future basic and translational research in this area.

333

## 334 **List of abbreviations**

335 **MP** macular pucker  
336 **sVEGFR2** soluble vascular endothelial growth factor receptor 2  
337 **mVEGFR2** membrane-bound VEGFR2  
338 **GWAS** genome-wide association studies  
339 **pQTL** protein quantitative trait loci  
340 **MR** mendelian randomization  
341 **IVW** inverse variance weighted



342 **MED27** mediator complex subunit 27  
343 **ERI1** exoribonuclease 1  
344 **LIMS2** LIM zinc finger domain containing 2  
345 **PCDH7** protocadherin 7  
346 **UKB-PPP** UK Biobank Pharma Proteomics Project  
347 **CADD** combined annotation-dependent depletion

348

#### 349 **Ethical statement**

350 In this study, we utilized publicly available GWAS data and ethical approvals were obtained in  
351 all original studies.

352

#### 353 **Competing interest**

354 The authors declare no competing financial interests.

355

#### 356 **Funding**

357 No funding source was applied to this study.

358

#### 359 **Author contributions**

360 Study design: J.G., Q.G.; data acquisition and analysis: J.G., Q.G.; figures, tables and original  
361 draft: J.G.; writing, reviewing and editing: J.G., Q.G.

362

#### 363 **Data sharing statement**

364 All GWAS data are publicly available and described in the data source section and  
365 supplementary table 1.

366

### 367 **Supplementary materials**

368 Supplementary materials associated with this article can be found in the online version, at xxx.

369

### 370 **References**

- 371 1. Kanukollu VM, Agarwal P. Epiretinal Membrane. StatPearls [Internet]. 2023.
- 372 2. Fung AT, Galvin J, Tran T. Epiretinal membrane: a review. Clinical & Experimental  
373 Ophthalmology. 2021;49(3):289-308.
- 374 3. Steinkerchner MS, Russell MW, Sharma N, Kumar M, Talcott KE, Singh RP. Long-Term  
375 Visual Outcomes in Patients with Idiopathic Epiretinal Membrane Surgery. Ophthalmic Surgery,  
376 Lasers and Imaging Retina. 2024;55(2):71-7.
- 377 4. Ishikura M, Muraoka Y, Nishigori N, Kogo T, Akiyama Y, Numa S, et al. Cellular  
378 Determinants of Visual Outcomes in Eyes with Epiretinal Membrane: Insights from Adaptive  
379 Optics Optical Coherence Tomography. Ophthalmology Science. 2024:100536.
- 380 5. Joshi M, Agrawal S, Christoforidis JB. Inflammatory mechanisms of idiopathic epiretinal  
381 membrane formation. Mediators of inflammation. 2013;2013(1):192582.
- 382 6. Hu Z, Mao X, Chen M, Wu X, Zhu T, Liu Y, et al. Single-cell transcriptomics reveals  
383 novel role of microglia in fibrovascular membrane of proliferative diabetic retinopathy. Diabetes.  
384 2022;71(4):762-73.

- 385 7. Chen Y-S, Hackett SF, Schoenfeld C-L, Viores MA, Viores SA, Campochiaro PA.  
386 Localisation of vascular endothelial growth factor and its receptors to cells of vascular and  
387 avascular epiretinal membranes. *British Journal of Ophthalmology*. 1997;81(10):919-26.
- 388 8. Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, et al. Detection of  
389 vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of  
390 proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.  
391 *Ophthalmologica*. 1998;212(6):410-4.
- 392 9. Tsanou E, Ioachim E, Stefaniotou M, Gorezis S, Charalabopoulos K, Bagli H, et al.  
393 Immunohistochemical study of angiogenesis and proliferative activity in epiretinal membranes.  
394 *International journal of clinical practice*. 2005;59(10):1157-61.
- 395 10. Cao Y, Langer R, Ferrara N. Targeting angiogenesis in oncology, ophthalmology and  
396 beyond. *Nature Reviews Drug Discovery*. 2023;22(6):476-95.
- 397 11. Jeong J-H, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues.  
398 *Archives of Pharmacal Research*. 2021;44(1):1-15.
- 399 12. Simons M, Gordon E, Claesson-Welsh L. Mechanisms and regulation of endothelial  
400 VEGF receptor signalling. *Nature reviews Molecular cell biology*. 2016;17(10):611-25.
- 401 13. Peach CJ, Mignone VW, Arruda MA, Alcobia DC, Hill SJ, Kilpatrick LE, et al.  
402 Molecular pharmacology of VEGF-A isoforms: binding and signalling at VEGFR2. *International*  
403 *journal of molecular sciences*. 2018;19(4):1264.
- 404 14. Albuquerque RJ, Hayashi T, Cho WG, Kleinman ME, Dridi S, Takeda A, et al.  
405 Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous  
406 inhibitor of lymphatic vessel growth. *Nature medicine*. 2009;15(9):1023-30.

- 407 15. Uehara H, Cho Y, Cahoon J, Archer B, Ambati B. Splicing shift from membrane bound  
408 VEGF receptor 2 to soluble VEGFR2 using morpholino oligomer suppresses suture induced  
409 corneal angiogenesis and lymphangiogenesis, and suppresses corneal graft rejection.  
410 *Investigative Ophthalmology & Visual Science*. 2012;53(14):2406-.
- 411 16. Noma H, Funatsu H, Mimura T, Eguchi S. Vascular endothelial growth factor receptor-2  
412 in macular oedema with retinal vein occlusion. *Ophthalmic Research*. 2012;48(1):56-8.
- 413 17. Noma H, Funatsu H, Mimura T, Eguchi S, Shimada K. Role of soluble vascular  
414 endothelial growth factor receptor-2 in macular oedema with central retinal vein occlusion.  
415 *British journal of ophthalmology*. 2011;95(6):788-92.
- 416 18. Sanderson E, Glymour MM, Holmes MV, Kang H, Morrison J, Munafò MR, et al.  
417 Mendelian randomization. *Nature Reviews Methods Primers*. 2022;2(1):6.
- 418 19. Schmidt AF, Finan C, Gordillo-Marañón M, Asselbergs FW, Freitag DF, Patel RS, et al.  
419 Genetic drug target validation using Mendelian randomisation. *Nature communications*.  
420 2020;11(1):3255.
- 421 20. Zuber V, Grinberg NF, Gill D, Manipur I, Slob EA, Patel A, et al. Combining evidence  
422 from Mendelian randomization and colocalization: Review and comparison of approaches. *The*  
423 *American Journal of Human Genetics*. 2022;109(5):767-82.
- 424 21. Evangelou E, Ioannidis JP. Meta-analysis methods for genome-wide association studies  
425 and beyond. *Nature Reviews Genetics*. 2013;14(6):379-89.
- 426 22. Bowden J, Holmes MV. Meta-analysis and Mendelian randomization: a review. *Research*  
427 *synthesis methods*. 2019;10(4):486-96.
- 428 23. Sun BB, Maranville JC, Peters JE, Stacey D, Staley JR, Blackshaw J, et al. Genomic atlas  
429 of the human plasma proteome. *Nature*. 2018;558(7708):73-9.

- 430 24. Gudjonsson A, Gudmundsdottir V, Axelsson GT, Gudmundsson EF, Jonsson BG, Launer  
431 LJ, et al. A genome-wide association study of serum proteins reveals shared loci with common  
432 diseases. *Nature communications*. 2022;13(1):480.
- 433 25. Ferkingstad E, Sulem P, Atlason BA, Sveinbjornsson G, Magnusson MI, Styrismisdottir  
434 EL, et al. Large-scale integration of the plasma proteome with genetics and disease. *Nature*  
435 *genetics*. 2021;53(12):1712-21.
- 436 26. Sun BB, Chiou J, Traylor M, Benner C, Hsu Y-H, Richardson TG, et al. Plasma  
437 proteomic associations with genetics and health in the UK Biobank. *Nature*.  
438 2023;622(7982):329-38.
- 439 27. Kurki MI, Karjalainen J, Palta P, Sipilä TP, Kristiansson K, Donner KM, et al. FinnGen  
440 provides genetic insights from a well-phenotyped isolated population. *Nature*.  
441 2023;613(7944):508-18.
- 442 28. Willer CJ, Li Y, Abecasis GR. METAL: fast and efficient meta-analysis of genomewide  
443 association scans. *Bioinformatics*. 2010;26(17):2190-1.
- 444 29. Maintainer BP. liftOver: Changing genomic coordinate systems with rtracklayer::liftOver.  
445 R package version 1.28.0, <https://www.bioconductor.org/help/workflows/liftOver/>.2024.
- 446 30. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ. Second-generation  
447 PLINK: rising to the challenge of larger and richer datasets. *Gigascience*. 2015;4(1):s13742-015-  
448 0047-8.
- 449 31. Ochoa D, Hercules A, Carmona M, Suveges D, Baker J, Malangone C, et al. The next-  
450 generation Open Targets Platform: reimagined, redesigned, rebuilt. *Nucleic acids research*.  
451 2023;51(D1):D1353-D9.

- 452 32. Rentsch P, Witten D, Cooper GM, Shendure J, Kircher M. CADD: predicting the  
453 deleteriousness of variants throughout the human genome. *Nucleic acids research*.  
454 2019;47(D1):D886-D94.
- 455 33. Burgess S, Thompson SG, Collaboration CCG. Avoiding bias from weak instruments in  
456 Mendelian randomization studies. *International journal of epidemiology*. 2011;40(3):755-64.
- 457 34. Skrivankova VW, Richmond RC, Woolf BA, Yarmolinsky J, Davies NM, Swanson SA, et  
458 al. Strengthening the reporting of observational studies in epidemiology using Mendelian  
459 randomization: the STROBE-MR statement. *Jama*. 2021;326(16):1614-21.
- 460 35. Verbanck M, Chen C-Y, Neale B, Do R. Detection of widespread horizontal pleiotropy in  
461 causal relationships inferred from Mendelian randomization between complex traits and  
462 diseases. *Nature genetics*. 2018;50(5):693-8.
- 463 36. Burgess S, Butterworth A, Thompson SG. Mendelian randomization analysis with  
464 multiple genetic variants using summarized data. *Genetic epidemiology*. 2013;37(7):658-65.
- 465 37. Bowden J, Davey Smith G, Burgess S. Mendelian randomization with invalid  
466 instruments: effect estimation and bias detection through Egger regression. *International journal*  
467 *of epidemiology*. 2015;44(2):512-25.
- 468 38. Burgess S, Bowden J, Fall T, Ingelsson E, Thompson SG. Sensitivity analyses for robust  
469 causal inference from Mendelian randomization analyses with multiple genetic variants.  
470 *Epidemiology*. 2017;28(1):30-42.
- 471 39. Hemani G, Tilling K, Davey Smith G. Orienting the causal relationship between  
472 imprecisely measured traits using GWAS summary data. *PLoS genetics*. 2017;13(11):e1007081.

- 473 40. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C, et al.  
474 Bayesian test for colocalisation between pairs of genetic association studies using summary  
475 statistics. *PLoS genetics*. 2014;10(5):e1004383.
- 476 41. Liu B, Gloudemans MJ, Rao AS, Ingelsson E, Montgomery SB. Abundant associations  
477 with gene expression complicate GWAS follow-up. *Nature genetics*. 2019;51(5):768-9.
- 478 42. Wang L-C, Hung K-H, Hsu C-C, Chen S-J, Li W-Y, Lin T-C. Assessment of retinal  
479 pigment epithelial cells in epiretinal membrane formation. *Journal of the Chinese Medical*  
480 *Association*. 2015;78(6):370-3.
- 481 43. Xu B, Zhou L, Chen Q, Zhang J, Huang L, Wang S, et al. Role of VEGFR2 in mediating  
482 endoplasmic reticulum stress under glucose deprivation and determining cell death, oxidative  
483 stress, and inflammatory factor expression. *Frontiers in Cell and Developmental Biology*.  
484 2021;9:631413.
- 485
- 486
- 487
- 488
- 489
- 490
- 491
- 492
- 493
- 494
- 495

496 **Figure legends**

497 **Figure 1. Study design and datasets.** sVEGFR2, soluble vascular endothelial growth factor

498 receptor 2; pQTL, protein quantitative trait loci; GWAS, genome-wide association studies; MR,

499 mendelian randomization; MR-PRESSO, MR Pleiotropy RESidual Sum and Outlier; LD, linkage

500 disequilibrium; SNP, single nucleotide polymorphism; Interval study, Sun BB. et al. 2018 Nature

501 (ref. 23); AGES study, Gudjonsson A. et al. 2022 Nature Communications (ref. 24); DECODE

502 study, Ferkingstad E. et al. 2021 Nature Genetics (ref. 25); UKB-PPP (UK Biobank Pharma

503 Proteomics Project) study, Sun BB. et al. 2023 Nature (ref. 26).

504

505

506

507

508

509

510

511

512

513

514

515

516

517



518 **Figure 2. *Cis*-MR results of IVW method for the effects of sVEGFR2 levels on macular**  
519 **pucker.** Results were reported as odds ratio (OR) with 95% confidence interval (CI) per one-  
520 standard deviation increase in sVEGFR2 levels; statistical tests were two-tailed;  $P < 0.05$  was  
521 considered significant; IVW, Inverse variance weighted; NSNP, number of single nucleotide  
522 polymorphism; Meta-analysis, combined data of Interval, AGES, and DECODE studies.

523

524

525

526

527

528

529

530

531

532

533

534

535

536

537

538

539

540

541 **Figure 3. Colocalization of sVEGFR2 pQTL and macular pucker.**

542 Bayesian colocalization analysis for sVEGFR2 pQTL from Interval (A), AGES (B), DECODE  
543 (C), meta-analysis (D), and UKB-PPP (E) and macular pucker within  $\pm 100$  kb around the  
544 *VEGFR2* gene (chromosome 4, position 55,078,481-55,125,595). A posterior probability of  
545 hypothesis 4 (PPH<sub>4</sub>) > 0.8 indicated strong evidence of colocalization. In the regional plots, each  
546 dot represented a genetic variant, and the candidate causal variant was depicted as a purple  
547 diamond. The color of other variants indicated their linkage disequilibrium ( $r^2$ ).

548

549

550

551

552

553

554

555

556

557

558

559

560

561

562

563

564 **Supplementary figure 1. Q-Q plots and Manhattan plots of the sVEGFR2 pQTL.** Mapped  
565 genes for GWAS-wide significant variants ( $P < 5 \times 10^{-8}$ ) in the Manhattan plot for the meta-  
566 analysis of the three independent studies were shown.

567

568

569

570

571

572

573

574

575

576

577

578

579

580

581

582

583

584

585

586

587 **Supplementary figure 2. Scatter plots and forest plots in *cis*-MR analysis.** In scatter plots, the  
588 x-axis shows the effect of each SNP on sVEGFR2 levels. The y-axis shows the effect of each  
589 SNP on macular pucker (MP). The regression lines for inverse variance weighted (IVW),  
590 weighted median, MR-egger, simple mode, weighted mode method are shown. In forest plots,  
591 the x- axis shows the *cis*-MR effect size for sVEGFR2 levels on macular pucker. The y-axis  
592 shows the analysis for each of the SNPs and for the SNPs in total using the MR-egger and IVW  
593 methods. The data are presented as raw  $\beta$  values with corresponding 95% confidence intervals.  
594 (A) Interval sVEGFR2 on MP; (B) AGES sVEGFR2 on MP; (C) DECODE sVEGFR2 on MP;  
595 (D) Meta-analysis sVEGFR2 on MP; (E) UKB-PPP sVEGFR2 on MP.

596

597

598

599

600

601

602

603

604

605

606

607

608

609 **Supplementary figure 3. Leave-one-out plots of cis-MR analysis for the effect of sVEGFR2**  
610 **levels on macular pucker.** The x-axis shows the *cis*- MR leave-one-out sensitivity analysis for  
611 the effect of sVEGFR2 levels on macular pucker. The y-axis shows the analysis for leave-one-  
612 out of SNPs and the effect of the total SNPs on macular pucker. The data are presented as raw  $\beta$   
613 values with corresponding 95% confidence intervals.

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631 **Supplementary figure 4. *Cis*-MR analysis using IVW method for the effects of sVEGFR2**  
632 **levels on other eye diseases.** Results were reported as odds ratio (OR) with 95% confidence  
633 interval (CI) per one-standard deviation increase in sVEGFR2 levels; statistical tests were two-  
634 tailed;  $P < 0.05$  was considered significant; IVW, Inverse variance weighted; NSNP, number of  
635 single nucleotide polymorphism; Meta-analysis, combined data of Interval, AGES, and  
636 DECODE studies.

## Protein measured by SomaScan

### sVEGFR2 pQTL

Interval study  
(n=3301)

### sVEGFR2 pQTL

AGES study  
(n=5361)

### sVEGFR2 pQTL

DECODE study  
(n=35559)

**sVEGFR2 pQTL:**  
**Meta-analysis** of  
n=44221 individuals  
and >25M variants

- 30 GWAS significant loci ( $P < 5e-8$ )
- 6 novel loci (outside of  $\pm 500$ kb of loci in parental studies)

- 4 novel loci after excluding loci of UKB-PPP study (outside of  $\pm 500$ kb of reported loci)

## Protein measured by Olink

**sVEGFR2 pQTL:**  
from UKB-PPP  
study (n=33822  
Europeans and >  
20M variants)

**cis-SNPs** associated with  
sVEGFR2

- $P < 5e-8$ ;
- LD clumping  $R^2 = 0.1$  with 100kb window;
- $\pm 100$ kb of *VEGFR2* gene;
- F-statistic > 10

### **cis-MR;**

Harmonization;  
MR-PRESSO;  
MR-Egger intercept;  
Cochran's Q;  
Reverse causality

### **Macular pucker**

(4599 cases and 413784  
controls from FinnGen)

### **Colocalization**

( $\pm 100$ kb of *VEGFR2* gene)













